Difference between revisions of "Team:BGU Israel/Experiments"

Line 195: Line 195:
 
</div>
 
</div>
  
       <div id="Tec-Monterrey" class="bg-grey">
+
       <div id="Electroporation" class="bg-grey">
 
<div class="container text-center">
 
<div class="container text-center">
 
<div class="col-sm-8 col-sm-offset-2">
 
<div class="col-sm-8 col-sm-offset-2">
 
   <div class="row">
 
   <div class="row">
       <h1>Tec-Monterrey</h1>
+
       <h1>Electroporation Transfection</h1>
 
<p>
 
<p>
 
     <b><u>Title</u>: </b>
 
     <b><u>Title</u>: </b>

Revision as of 13:08, 10 October 2018

OriginALS

OriginALS

Experiments

Tech

Calcium Phosphate Transfection

Title: Transfection to microglia and astrocytes via “calcium phosphate” method.

Conducted by: Sagi Angel

Date: 3-7.6.18

Aim: In this experiment we have tried to use the calcium phosphate protocol in order to transfect microglia astrocytes and HEK as control in GFP gene. The use of HEK cells as control, is due to its ability to be transfected relatively easily by the various techniques, including calcium phosphate method.

Importance: This experiment was carried out in parallel with experiments using different methods of transfection (different reagents and electroporation) in order to find an efficient way of inserting our plasmids into astrocytes and microglia for the continuation of the project.

Experiments

Protocols

Notebook

Calcium Phosphate

Theoretical background:
Transfection of DNA into cells via calcium phosphate is a simple, efficient and inexpensive method is to transfect eukaryotic cells via calcium phosphate co-precipitation with DNA (Graham and van der Eb, 1973). The insoluble calcium phosphate precipitate with the attached DNA adheres to the cell surface and is brought into the cells by endocytosis. Calcium phosphate transfection has been optimized and widely used with many adherent and non-adherent cell lines (Jordan et al., 1996). Calcium phosphate transfection can result in transient expression of the delivered DNA in the target cell, or establishment of stable cell lines.

Procedure:

The ingredients prepared according to the protocol with the GFP gene plasmid:

  1. 23 ul of PUC GFP DNA ,187 ul OF 1M CaCl2, DDW up to 750ul + 750 HEBSX2
  2. All ingredients were made and then filtered in 0.22 filter for sterile solution
  3. The ingredients were mixed for 30 minutes in a 1.5 ml Eppendorf for the 6 wells plate (250ul of complete reagent for each well)
  4. In the 6 wells there were 2 options for the transformation:

    a) Medium removed, 250ul reagent added. after 30 min new medium(2.5ml) added

    b) 250ul reagent added + old medium(2.5ml)

  5. After 8 hours all old medium removed and added new 2.5ml of relevantmedium

Design:
[ADD PHOTO OR TABLE]

References:

  1. Chen, Y., Lu, B., Yang, Q., Fearns, C., Yates, J. R., 3rd and Lee, J. D. (2009). Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69(8): 3713-3720.
  2. Graham, F. L. and van der Eb, A. J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52(2): 456-67.
  3. Jordan, M., Schallhorn, A. and Wurm, F. M. (1996). Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 24(4): 596-601.

Electroporation Transfection

Title: Knockout of IKK-β gene in microglia cell-line.

Conducted by: Einan Farhi and Mor Pasy

Date: 15.7.18

Experiment goal and significance: The objective is to create a stable cell-line of the BV2 cells with a knockout mutation of the Inhibitor of Nuclear Factor kappa-B Kinase subunit beta (IKBKB) gene. With which, we aim to demonstrate how targeting the Nuclear Factor kappa B (NFκB) pathway will diminish the amount of inflammation promoting cytokines produced by the immune representative cells of the brain.

Experiments

Protocols

Notebook

Electroporation

Theoretical background:
In the experiment we used a px601 commercial vector designed to express a Staphylococcus aureus (SaCas9) conjugated with a Green Fluorescent Protein (GFP). Mor P. cloned the F4/80 promoter into the vector upstream of the Cas9-GFP construct instead of the original Cytomegalovirus (CMV) promoter. This promoter is considered to be expressed highly in microglia versus the other types of cells of the brain1. Into the guide RNA sequence of the vector was cloned a targeting sequence complementary to sequences that reside in various exons of the IKBKB gene. Generally, the CRISPR/Cas9 system is used to deliver a sequence-wise accurate double strand break which should dramatically increase the chances of a knockout mutation in the targeted gene2. The knockout of IKK-β should, in theory, decrease the amount of Inhibitor of kappa-B (IκB) that is sent to degradation and thus maintain a persistent inhibition of NFκB. A stronger inhibition of the NFκB complex might produce a weaker expression of its target genes, among them: Interleukin 1 subunit α (Il1α) 3 and Tumor Necrosis Factor subunit α (TNFα)4.

Procedure:

  1. Cloning of plasmid.
  2. Electroporation with plasmid.
  3. Validation of transfection success according to expression of GFP.
  4. Validation of resulted mutation using the T7E1 assay.
  5. Checking for a diminished expression of IKK-β using Western Blot analysis.
  6. Cytokine assay to determine if an inhibition of the cytokine production was achieved>

[Picture of the experimental procedure will be added]

Design :

Each transfection mixture was pipetted evenly into 6 wells of a 24 well-plate. DNA quantities that were used are as following: 2.5, 5, 9 μg of DNA. As a positive control, BV-2 cells were transfected with 5 μg pAc-GFP and as a negative control cells were electroporated with no plasmid and also seeded without electroporation. Here is a schematic diagram of the wells mentioned:

BV2 electroporation with px601-f4/80-g2; 2.5x106 cells per cuvette; A-030 program

2.5 μg DNA

2.5 μg DNA

2.5 μg DNA

2.5 μg DNA

2.5 μg DNA

2.5 μg DNA

5 μg DNA

5 μg DNA

5 μg DNA

5 μg DNA

5 μg DNA

5 μg DNA

9 μg DNA

9 μg DNA

9 μg DNA

9 μg DNA

9 μg DNA

9 μg DNA

No DNA

No DNA

No DNA

No DNA

No DNA

No DNA

No transfection

No transfection

No transfection

No transfection

No transfection

No transfection

References:

  1. Helen L. Fitzsimons, Matthew J. During, CHAPTER 1 - Design and Optimization of Expression Cassettes Including Promoter Choice and Regulatory Elements, Gene Therapy of the Central Nervous System, Academic Press, 2006, Pages 3-16.
  2. Genome engineering using the CRISPR-Cas9 system. 2013. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Nat Protoc. 8(11):2281-308.
  3. Mori N and Prager D. (1996). Blood, 87, 3410 ± 3417.
  4. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA and Jongeneel CV. (1990). J. Exp. Med., 171, 35 ± 47.

US_AFRL_CarrollHS

Purpose of collaboration:
Increase exposure for our team on social media.

Description:
We happily took part in a marketing project spearheaded by US_AFRL_CarrollHS called “Mike the Microbe". We created caricatures of ourselves with the Mike the Microbe character and posted them on Instagram. This lead to further exposure to other iGEM teams and was a lot of fun!

MichiganState

Purpose of collaboration:
Present projects and receive feedback.

Description:
The group contacted us through Instagram, and in fact was the first group we talked to through social media. We decided to organize a Skype call in which we presented our projects to each other. It was very interesting to meet and discuss our project with another group and we enjoyed getting to know the team members from the University of Michigan.

OriginALS

About Us


The BGU-iGEM team “OriginALS” hopes to develop an innovative therapeutic approach to prolong the life expectancy of ALS patients, using Synthetic Biology. We are dedicated to promoting ALS awareness and research in Israel through public engagement and educational activities.